Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radiation and immunotherapy join forces in new cancer trial

NCT ID NCT07277777

Disease control Sponsor: Li Min Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a special type of radiation (called 125I seed brachytherapy) to standard immunotherapy can help shrink tumors and keep them from growing back. The trial will include 90 adults with various cancers that have come back or spread. Half will get the combination treatment, and half will get immunotherapy alone. The goal is to see if the radiation makes the immune system work better against the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 80 years. * Histologically or clinically confirmed primary, recurrent, or metastatic malignant tumor. * At least one measurable lesion according to RECIST 1.1 or iRECIST. * Tumor site suitable for 125I seed implantation under CT or PET/CT guidance. * Planned to receive or eligible to receive an immune checkpoint inhibitor (ICI). * ECOG performance status 0-2. * Adequate organ function: ANC ≥ 1.5 × 10⁹/L Platelets ≥ 80 × 10⁹/L Hemoglobin ≥ 90 g/L AST/ALT ≤ 3 × ULN (≤ 5 × ULN for liver metastasis) Creatinine clearance ≥ 50 mL/min * Life expectancy ≥ 3 months. * Ability to understand and sign informed consent. Exclusion Criteria: * Prior I-125 seed implantation at the planned treatment site. * Active uncontrolled infection or systemic inflammatory disease. * Known history of autoimmune disease requiring systemic immunosuppression. * Prior treatment with immune checkpoint inhibitors within the last 4 weeks. * Uncontrolled coagulopathy or contraindication to interventional seed implantation: INR \> 1.5 Platelets \< 50 × 10⁹/L * Tumor location that poses unacceptable procedural risk, including inability to obtain a safe puncture path. * Severe cardiopulmonary dysfunction (e.g., heart failure, unstable arrhythmia, severe COPD). * Pregnancy or breastfeeding. * Known allergy or contraindication to radiopharmaceuticals, contrast agents, or anesthesia agents used during implantation. * Any condition that, in the investigator's judgment, makes the participant unsuitable for the study (e.g., poor compliance, severe psychiatric disorder).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malignant tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Malignant tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The 960th Hospital of People's Liberation Army (PLA)

    Jinan, Shandong, 250031, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.